Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 3, pp 229–233 | Cite as

Carboplatin and etoposide in advanced lung cancer: — a phase I study

  • K. Liippo
  • V. Nikkanen
  • E. Heinonen
Original Articles Carboplatin, Advanced Lung Cancer, Phase I Study

Summary

This phase I study was carried out to determine the maximal tolerated dose of carboplatin (Car) together with a fixed dose of etoposide (E) and to recommend the optimal dose for a phase II study. The dose of E was 100 mg/m2 given i.v. on days 1–3, and the starting dose of Car was 200 mg/m2 given i.v. on day 1. The dose was escalated until WHO grade 4 toxicity developed after two treatment cycles in more than one-third of the patients. A total of 33 patients with advanced lung cancer entered the trial. The maximal tolerated toxicity of the combination was reached at a dose of 500 mg/m2 Car. Myelosuppression was moderate, and hematological toxicity of WHO grade 4 was encountered in one of five patients at 475 mg/m2 and in two out of five patients at 500 mg/m2. The main toxic effects were leucopenia and thrombocytopenia. The frequency of treatment-related infections was low and no deaths were caused by treatment. There was a significant overall correlation between the platelet nadir and creatinine clearance. One complete response and three partial responses were achieved after two treatment cycles. Based on the results of the present study, the dose of carboplatin (combined with 100 mg/m2 eposide given on days 1–3) recommended for phase II studies is 450 mg/m2.

Keywords

Lung Cancer Creatinine Cancer Research Toxic Effect Thrombocytopenia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arnold A, Williams CJ (1979) Small-cell lung cancer. A curable disease. Br J Dis Chest 73: 327–348Google Scholar
  2. 2.
    Bishop JF, Raghavan D, Stuart-Harris R, (1987) Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 5: 1574–1578Google Scholar
  3. 3.
    Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxal FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756Google Scholar
  4. 4.
    Eagan RT, Ingle JN, Creagan ET, VP 16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 62: 843–844Google Scholar
  5. 5.
    Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY (1984) Pharmacokinetics and dosage reduction ofcis-diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432–5438Google Scholar
  6. 6.
    Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E (1983) Phase II study of JM-8, a new platinum analog in advanced ovarian carcinoma. Cancer Treat Rep 67: 997–1000Google Scholar
  7. 7.
    Evans WK, Eisenhauer E, Hughes P, (1988) VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Br J Cancer 58: 464–468Google Scholar
  8. 8.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetics ofcis-diammine-1,1-cyclobutane-dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693–1697Google Scholar
  9. 9.
    Leventhal BG, Wittes RE (eds) (1988) Research methods in clinical oncology. Raven Press, New YorkGoogle Scholar
  10. 10.
    Miller AB, Hoogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47: 207–214Google Scholar
  11. 11.
    Olver IN, Donehower RC, Van Echo DA, Ettinger DS, Aisner J (1986) Phase II trial of carboplatin in non-small cell lung cancer. Cancer Treat Rep 70: 421–422Google Scholar
  12. 12.
    Schabel FM, Trader MW, Laster WK, (1979)cis-Dichlorodiammineplatinum(II). Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459–1473Google Scholar
  13. 13.
    Smith IE, Harland SJ, Robinson BA (1985) Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69: 43–46Google Scholar
  14. 14.
    Smith IE, Evans BD, Gore ME, (1987) Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5: 185–189Google Scholar
  15. 15.
    Tamura T, Saijo N, Shinkai T, Eguchi K, Sasaki Y (1988) Phase II study of carboplatin in small cell lung cancer. Jpn J Clin Oncol 18: 27–32Google Scholar
  16. 16.
    Tucker RK, Ferguson A, Van Wyk C, Scaly R, Hewitsen R, Levin W (1978) Chemotherapy of small cell carcinoma of the lung with VP 16-213. Cancer 41: 1710–1714Google Scholar
  17. 17.
    Tueni E, Sculier J-P, Klastersky J (1988) Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer. Eur J Cancer Clin Oncol 24: 963–967Google Scholar
  18. 18.
    Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37: 162–190Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • K. Liippo
    • 1
  • V. Nikkanen
    • 2
  • E. Heinonen
    • 3
  1. 1.Department of Diseases of the ChestUniversity Central Hospital of TurkuTurkuFinland
  2. 2.Department of RadiotherapyUniversity Central Hospital of TurkuTurkuFinland
  3. 3.Department of Farmos Group LtdTurkuFinland

Personalised recommendations